Two major strategies target senescent cells in neurodegeneration: suppressing their inflammatory secretome (SASP) via JAK/STAT inhibitors, or eliminating them via senolytics. This tradeoff analysis challenge asks which strategy better preserves cognitive function, and whether timing (early vs late disease) determines optimal choice. Key concern: senolytic elimination may remove cells with residual beneficial functions, while SASP suppression may allow accumulation of dysfunctional cells. Falsifiable prediction: JAK inhibition started at 3 months and senolytics started at 9 months in 5xFAD mice should show distinct cognitive and biomarker profiles.